Any feedback?
Literature summary for 3.4.22.1 extracted from
- Inhibitors of cathepsin B (2006), Curr. Med. Chem., 13, 2309-2327.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | cathepsin B inhibitors have a potential in cancer chemotherapy | Homo sapiens |
Crystallization (Commentary)
| Crystallization (Comment) | Organism |
|---|---|
- |
Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| (2R,3R)-3-(((1S)-1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid | - |
Homo sapiens |  |
| (2R,3R)-3-(((1S)-3-methyl-1-[(3-methylbutoxy)carbonyl]butyl)carbamoyl)aziridine-2-carboxylic acid | - |
Homo sapiens | |
| (2S,3S)-3-(((1S)-1-[(4-([(benzyloxy)carbonyl]amino)butyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid | - |
Homo sapiens | |
| (2S,3S)-3-(((1S)-1-[(4-aminobutyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid | - |
Homo sapiens | |
| (2S,3S)-3-(((1S)-1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid | - |
Homo sapiens | |
| (2S,3S)-3-(((1S)-1-[(7-aminoheptyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid | - |
Homo sapiens | |
| (2S,3S)-3-(((1S)-3-methyl-1-[(3-methylbutoxy)carbonyl]butyl)carbamoyl)aziridine-2-carboxylic acid | - |
Homo sapiens | |
| (2S,3S)-3-(((1S)-3-methyl-1-[(3-methylbutyl)carbamoyl]butyl)carbamoyl)oxirane-2-carboxylic acid | - |
Homo sapiens | |
| (2S,3S)-3-([(1S)-1-(benzylcarbamoyl)-3-methylbutyl]carbamoyl)oxirane-2-carboxylic acid | - |
Homo sapiens | |
| 1-[N-(tert-butoxycarbonyl)-L-phenylalanyl]-3-(ethoxycarbonyl)aziridine-2-carboxylic acid | - |
Homo sapiens | |
| 1-[N-(tert-butoxycarbonyl)-L-phenylalanyl]aziridine-2,3-dicarboxylic acid | - |
Homo sapiens | |
| 3-(([(3S)-3-((N-[(4-chloro-2-fluorophenyl)carbonyl]-3-methyl-L-phenylalanyl)amino)-3-cyanopropyl]oxy)methyl)benzoic acid | IC50: 0.000002 mM | Homo sapiens | |
| 3-(([(3S)-3-cyano-3-([3-methyl-N-(phenylcarbonyl)-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid | IC50: 0.0000094 mM | Homo sapiens | |
| 3-(([(3S)-3-cyano-3-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid | IC50: 0.0000018 mM | Homo sapiens | |
| 3-([(2R)-2-cyano-2-([3-methyl-N-(2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid | IC50: 0.0000049 mM | Homo sapiens | |
| 3-([(2R)-2-cyano-2-([3-methyl-N-(3-oxo-2,3-dihydro-1H-inden-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid | IC50: 0.0000053 mM | Homo sapiens | |
| 3-([(2R)-2-cyano-2-([N-(1,1-dimethyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methyl-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid | IC50: 0.0000053 mM | Homo sapiens | |
| 3-methylbutyl N-[(3-methoxy-1,2,4-thiadiazolidin-5-yl)carbamoyl]-L-leucyl-L-prolinate | IC50: 0.367 mM | Homo sapiens | |
| 3-[(5S)-5-cyano-5-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)pentyl]benzoic acid | IC50: 0.000018 mM | Homo sapiens | |
| 4-(([(3S)-3-cyano-3-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid | IC50: 0.000005 mM | Homo sapiens | |
| 5,7-dihydroxy-2-(4-hydroxy-3-[7-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one | IC50: 0.00175 mM | Homo sapiens | |
| 5,7-dihydroxy-2-(4-hydroxy-3-[7-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one | IC50: 0.00168 mM | Homo sapiens | |
| 5,7-dihydroxy-2-(4-hydroxy-3-[7-methoxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one | IC50: 0.00055 mM | Homo sapiens | |
| 5-(((2R)-2-cyano-2-[(3-methyl-N-phenyl-L-phenylalanyl)amino]ethoxy)methyl)-2-fluorobenzoic acid | IC50: 0.0000122 mM | Homo sapiens | |
| 5-([(2R)-2-cyano-2-([3-methyl-N-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)-2-fluorobenzoic acid | IC50: 0.0000041 mM | Homo sapiens | |
| acetyl-Leu-Ile-arginal | IC50: 0.00015 mM | Homo sapiens | |
| acetyl-Leu-Leu-lysinal | IC50: 0.00013 mM | Homo sapiens | |
| acetyl-Leu-Phe-arginal | IC50: 0.0011 mM | Homo sapiens | |
| acetyl-Leu-Phe-lysinal | IC50: 0.0001 mM | Homo sapiens | |
| acetyl-Leu-Val-lysinal | IC50: 0.000004 mM | Homo sapiens | |
| acetyl-Phe-Val-arginal | IC50: 0.000039 mM | Homo sapiens | |
| AM4299A | irreversible inhibition, IC50: 0.000073 mM | Homo sapiens | |
| AM4299B | irreversible inhibition, IC50: 0.000130 mM | Homo sapiens | |
| benzyl N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-alanyl-L-phenylalaninate | IC50: 0.037 mM | Homo sapiens | |
| benzyl N-([(2R,3R)-3-(butoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-prolinate | - |
Homo sapiens | |
| benzyl N-([(2R,3R)-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucinate | - |
Homo sapiens | |
| benzyl N-([(2R,3R)-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucyl-L-prolinate | - |
Homo sapiens | |
| benzyl N-([(2R,3R)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-prolinate | - |
Homo sapiens | |
| benzyl N-([(2R,3R)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-prolinate | - |
Homo sapiens | |
| benzyl N-([(2S,3S)-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucinate | - |
Homo sapiens | |
| benzyl N-([(2S,3S)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-prolinate | - |
Homo sapiens | |
| benzyl N-[(3-carboxyaziridin-2-yl)carbonyl]-L-leucyl-L-prolinate | - |
Homo sapiens | |
| benzyl [(1R)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)carbamoyl)-2-methylpropyl]carbamate | IC50: 0.000044 mM | Homo sapiens | |
| benzyl [(1R)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-4-methylpentyl)carbamoyl)-2-methylpropyl]carbamate | IC50: 0.0290 mM | Homo sapiens | |
| benzyl [(1R)-1-([1-benzyl-2-hydroxy-2-(3-oxo-2-phenylcycloprop-1-en-1-yl)ethyl]carbamoyl)-2-methylpropyl]carbamate | IC50: more than 0.1 mM | Homo sapiens | |
| benzyl [(1R)-1-([2-hydroxy-1-methyl-2-(3-oxo-2-phenylcycloprop-1-en-1-yl)ethyl]carbamoyl)-2-methylpropyl]carbamate | IC50: 0.0229 mM | Homo sapiens | |
| benzyl [(1R)-2-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)amino)-1-methyl-2-oxoethyl]carbamate | IC50: 0.00945 mM | Homo sapiens | |
| benzyl [(1S)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)carbamoyl)-2-methylpropyl]carbamate | IC50: 0.00071 mM | Homo sapiens | |
| CA028 | irreversible inhibition, IC50: 0.000140 mM | Homo sapiens | |
| CA030 | irreversible inhibition, IC50: 0.00000438 mM | Homo sapiens | |
| CA074 | irreversible inhibition, IC50: 0.00000194 mM | Homo sapiens | |
| cathestatin A | irreversible inhibition, IC50: 0.000260 mM | Homo sapiens | |
| cathestatin B | irreversible inhibition, IC50: 0.000280 mM | Homo sapiens | |
| cathestatin C | irreversible inhibition, IC50: 0.000114 mM | Homo sapiens | |
| E-64 | irreversible inhibition, IC50: 0.000055 mM | Homo sapiens | |
| E-64c | irreversible inhibition, IC50: 0.00000870 mM | Homo sapiens | |
| estatin A | irreversible inhibition, IC50: 0.000270 mM | Homo sapiens | |
| estatin B | irreversible inhibition, IC50: 0.000320 mM | Homo sapiens | |
| ethyl (2R,3R)-3-(((1S)-1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl)carbamoyl)oxirane-2-carboxylate | - |
Homo sapiens | |
| ethyl (2S,3S)-3-(((1S)-3-methyl-1-[(3-methylbutyl)carbamoyl]butyl)carbamoyl)oxirane-2-carboxylate | - |
Homo sapiens | |
| ethyl 1-[(2R)-2-((1S)-1-(acetyloxy)-2-[((N-[(2,4-difluorophenyl)carbonyl]-L-phenylalanyl)amino)oxy]-2-oxoethyl)pentanoyl]prolinate | IC50: 4.4 mM | Homo sapiens | |
| leupeptin | IC50: 0.0000213 mM | Homo sapiens | |
| methyl N-([(2R,3R)-3-([(1R)-1-([(2S)-2-carboxypyrrolidin-1-yl]carbonyl)-3-methylbutyl]carbamoyl)oxiran-2-yl]carbonyl)-L-leucylglycylglycinate | - |
Homo sapiens | |
| methyl N-([(2S,3S)-3-([(1R)-1-([(2S)-2-carboxypyrrolidin-1-yl]carbonyl)-3-methylbutyl]carbamoyl)oxiran-2-yl]carbonyl)-L-leucylglycylglycinate | - |
Homo sapiens | |
| mizaridine | IC50: 0.00205 mM | Homo sapiens | |
| N-(((2R,3R)-3-[(1-methylethyl)carbamoyl]oxiran-2-yl)carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-(((2S,3S)-3-[(1-methylethyl)carbamoyl]oxiran-2-yl)carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-((1S)-2-[(2R,3R)-2-[(benzyloxy)carbonyl]-3-(ethoxycarbonyl)aziridin-1-yl]-1-methyl-2-oxoethyl)-Na-(tert-butoxycarbonyl)-L-phenylalaninamide | - |
Homo sapiens | |
| N-(3-carboxy-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline | IC50: 0.300 mM | Homo sapiens | |
| N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline | IC50: 0.0026 mM | Homo sapiens | |
| N-(3-methyl-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline | IC50: 0.447 mM | Homo sapiens | |
| N-(3-phenyl-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline | IC50: 0.074 mM | Homo sapiens | |
| N-([(2R,3R)-1-[N-(tert-butoxycarbonyl)-L-phenylalanyl]-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-([(2R,3R)-3-((5-amino-1-[(4-carbamimidamidobutyl)carbamoyl]pentyl)carbamoyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-([(2R,3R)-3-(butoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-([(2R,3R)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-arginine | - |
Homo sapiens | |
| N-([(2R,3R)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-([(2R,3R)-3-([(1R)-1-([(2S)-2-carboxypyrrolidin-1-yl]carbonyl)-3-methylbutyl]carbamoyl)oxiran-2-yl]carbonyl)-L-leucylglycyl-N-(6-[((2-[6-(diethylamino)-3-(diethyliminio)-3H-xanthen-9-yl]phenyl)carbonyl)amino]hexyl)glycinamide | - |
Homo sapiens | |
| N-([(2R,3R)-3-([(1R)-1-([(2S)-2-carboxypyrrolidin-1-yl]carbonyl)-3-methylbutyl]carbamoyl)oxiran-2-yl]carbonyl)-L-leucylglycyl-N-[6-((5-[(4R)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl)amino)hexyl]glycinamide | - |
Homo sapiens | |
| N-([(2R,3R)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-arginine | - |
Homo sapiens | |
| N-([(2R,3R)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-([(2S,3S)-1-[N-(tert-butoxycarbonyl)-L-phenylalanyl]-3-(ethoxycarbonyl)aziridin-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-([(2S,3S)-3-((5-amino-1-[(4-carbamimidamidobutyl)carbamoyl]pentyl)carbamoyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-([(2S,3S)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-([(2S,3S)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-leucine | - |
Homo sapiens | |
| N-([(2S,3S)-3-carboxyoxiran-2-yl]carbonyl)-L-leucyl-L-proline | - |
Homo sapiens | |
| N-[(1R)-1-cyano-2-([3-(2H-tetrazol-2-yl)benzyl]oxy)ethyl]-3-methyl-Na-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)-L-phenylalaninamide | IC50: 0.000005 mM | Homo sapiens | |
| N-[(1S)-3-(benzyloxy)-1-cyanopropyl]-Nalpha-(diphenylacetyl)-3-methyl-L-phenylalaninamide | IC50: 0.0000102 mM | Homo sapiens | |
| N-[(3-methoxy-1,2,4-thiadiazolidin-5-yl)carbamoyl]-L-leucyl-L-proline | IC50: 0.390 mM | Homo sapiens | |
| Na-[(benzyloxy)carbonyl]-N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-phenylalaninamide | IC50: 0.021 mM | Homo sapiens | |
| Nalpha-(tert-butoxycarbonyl)-N-((1S)-2-[(2R,3R)-2-carboxy-3-(ethoxycarbonyl)aziridin-1-yl]-1-methyl-2-oxoethyl)-L-phenylalaninamide | - |
Homo sapiens | |
| Nalpha-[(benzyloxy)carbonyl]-N-[(2R,3S)-2-(carboxyoxy)-4-oxoazetidin-3-yl]-L-phenylalaninamide | IC50: 0.00047 mM | Homo sapiens | |
| Nalpha-[(benzyloxy)carbonyl]-N-[(3S,4R)-2-oxo-4-phenoxyazetidin-3-yl]-L-phenylalaninamide | IC50: 0.00043 mM | Homo sapiens | |
| Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6R)-4,4-dioxido-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide | IC50: 0.00035 mM | Homo sapiens | |
| Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6R)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide | IC50: more than 0.00050 mM | Homo sapiens | |
| Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6S)-7-oxo-4-oxa-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide | IC50: 0.00176 mM | Homo sapiens | |
| Nalpha-[(benzyloxy)carbonyl]-N-[(6R)-4-oxido-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide | IC50: 0.0164 mM | Homo sapiens | |
| TMC-52A | irreversible inhibition, IC50: 0.000320 mM | Homo sapiens | |
| TMC-52B | irreversible inhibition, IC50: 0.000200 mM | Homo sapiens | |
| TMC-52C | irreversible inhibition, IC50: 0.000460 mM | Homo sapiens | |
| TMC-52D | irreversible inhibition, IC50: 0.000280 mM | Homo sapiens | |
| tokaramide A | IC50: 0.0000624 mM | Homo sapiens | |
| WF14861 | irreversible inhibition, IC50: 0.000016 mM | Homo sapiens | |
| WF14865A | irreversible inhibition, IC50: 0.0000084 mM | Homo sapiens | |
| WF14865B | irreversible inhibition, IC50: 0.000013 mM | Homo sapiens | |
| YM 51084 | IC50: 0.000012 mM | Homo sapiens | |
| Z-Phe-Ala-CH2-O-CO-(2,4,6-trimethyl)-Ph | - |
Homo sapiens | |
| Z-Phe-Ala-CH2-O-CO-(2,5-(CF3)2)-Ph | - |
Homo sapiens | |
| Z-Phe-Ala-CH2-O-CO-(2,6-(CF3)2)-Ph | - |
Homo sapiens | |
| Z-Phe-Cys(SBzl)-CH2-O-CO-(2,6-(CF3)2)-Phe | - |
Homo sapiens | |
| Z-Phe-Lys-CH2-O-CO-(2,4,6-trimethyl)-Ph | - |
Homo sapiens | |
Molecular Weight [Da]
| Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
|---|---|---|---|
| 30000 | - |
x * 30000, SDS-PAGE | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | P07858 | - |
- |
Subunits
| Subunits | Comment | Organism |
|---|---|---|
| ? | x * 30000, SDS-PAGE | Homo sapiens |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| CatB | - |
Homo sapiens |
| cathepsin B | - |
Homo sapiens |
IC50 Value
| IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
|---|---|---|---|---|---|
| 0.0000018 | - |
IC50: 0.0000018 mM | Homo sapiens | 3-(([(3S)-3-cyano-3-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid | |
| 0.00000194 | - |
irreversible inhibition, IC50: 0.00000194 mM | Homo sapiens | CA074 | |
| 0.000002 | - |
IC50: 0.000002 mM | Homo sapiens | 3-(([(3S)-3-((N-[(4-chloro-2-fluorophenyl)carbonyl]-3-methyl-L-phenylalanyl)amino)-3-cyanopropyl]oxy)methyl)benzoic acid | |
| 0.000004 | - |
IC50: 0.000004 mM | Homo sapiens | acetyl-Leu-Val-lysinal | |
| 0.0000041 | - |
IC50: 0.0000041 mM | Homo sapiens | 5-([(2R)-2-cyano-2-([3-methyl-N-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)-2-fluorobenzoic acid | |
| 0.00000438 | - |
irreversible inhibition, IC50: 0.00000438 mM | Homo sapiens | CA030 | |
| 0.0000049 | - |
IC50: 0.0000049 mM | Homo sapiens | 3-([(2R)-2-cyano-2-([3-methyl-N-(2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid | |
| 0.000005 | - |
IC50: 0.000005 mM | Homo sapiens | 4-(([(3S)-3-cyano-3-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid | |
| 0.000005 | - |
IC50: 0.000005 mM | Homo sapiens | N-[(1R)-1-cyano-2-([3-(2H-tetrazol-2-yl)benzyl]oxy)ethyl]-3-methyl-Na-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)-L-phenylalaninamide | |
| 0.0000053 | - |
IC50: 0.0000053 mM | Homo sapiens | 3-([(2R)-2-cyano-2-([3-methyl-N-(3-oxo-2,3-dihydro-1H-inden-5-yl)-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid | |
| 0.0000053 | - |
IC50: 0.0000053 mM | Homo sapiens | 3-([(2R)-2-cyano-2-([N-(1,1-dimethyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-methyl-L-phenylalanyl]amino)ethoxy]methyl)benzoic acid | |
| 0.0000084 | - |
irreversible inhibition, IC50: 0.0000084 mM | Homo sapiens | WF14865A | |
| 0.0000087 | - |
irreversible inhibition, IC50: 0.00000870 mM | Homo sapiens | E-64c | |
| 0.0000094 | - |
IC50: 0.0000094 mM | Homo sapiens | 3-(([(3S)-3-cyano-3-([3-methyl-N-(phenylcarbonyl)-L-phenylalanyl]amino)propyl]oxy)methyl)benzoic acid | |
| 0.0000102 | - |
IC50: 0.0000102 mM | Homo sapiens | N-[(1S)-3-(benzyloxy)-1-cyanopropyl]-Nalpha-(diphenylacetyl)-3-methyl-L-phenylalaninamide | |
| 0.000012 | - |
IC50: 0.000012 mM | Homo sapiens | YM 51084 | |
| 0.0000122 | - |
IC50: 0.0000122 mM | Homo sapiens | 5-(((2R)-2-cyano-2-[(3-methyl-N-phenyl-L-phenylalanyl)amino]ethoxy)methyl)-2-fluorobenzoic acid | |
| 0.000013 | - |
irreversible inhibition, IC50: 0.000013 mM | Homo sapiens | WF14865B | |
| 0.000016 | - |
irreversible inhibition, IC50: 0.000016 mM | Homo sapiens | WF14861 | |
| 0.000018 | - |
IC50: 0.000018 mM | Homo sapiens | 3-[(5S)-5-cyano-5-([N-(diphenylacetyl)-3-methyl-L-phenylalanyl]amino)pentyl]benzoic acid | |
| 0.0000213 | - |
IC50: 0.0000213 mM | Homo sapiens | leupeptin | |
| 0.000039 | - |
IC50: 0.000039 mM | Homo sapiens | acetyl-Phe-Val-arginal | |
| 0.000044 | - |
IC50: 0.000044 mM | Homo sapiens | benzyl [(1R)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)carbamoyl)-2-methylpropyl]carbamate | |
| 0.000055 | - |
irreversible inhibition, IC50: 0.000055 mM | Homo sapiens | E-64 | |
| 0.0000624 | - |
IC50: 0.0000624 mM | Homo sapiens | tokaramide A | |
| 0.000073 | - |
irreversible inhibition, IC50: 0.000073 mM | Homo sapiens | AM4299A | |
| 0.0001 | - |
IC50: 0.0001 mM | Homo sapiens | acetyl-Leu-Phe-lysinal | |
| 0.000114 | - |
irreversible inhibition, IC50: 0.000114 mM | Homo sapiens | cathestatin C | |
| 0.00013 | - |
IC50: 0.00013 mM | Homo sapiens | acetyl-Leu-Leu-lysinal | |
| 0.00013 | - |
irreversible inhibition, IC50: 0.000130 mM | Homo sapiens | AM4299B | |
| 0.00014 | - |
irreversible inhibition, IC50: 0.000140 mM | Homo sapiens | CA028 | |
| 0.00015 | - |
IC50: 0.00015 mM | Homo sapiens | acetyl-Leu-Ile-arginal | |
| 0.0002 | - |
irreversible inhibition, IC50: 0.000200 mM | Homo sapiens | TMC-52B | |
| 0.00026 | - |
irreversible inhibition, IC50: 0.000260 mM | Homo sapiens | cathestatin A | |
| 0.00027 | - |
irreversible inhibition, IC50: 0.000270 mM | Homo sapiens | estatin A | |
| 0.00028 | - |
irreversible inhibition, IC50: 0.000280 mM | Homo sapiens | cathestatin B | |
| 0.00028 | - |
irreversible inhibition, IC50: 0.000280 mM | Homo sapiens | TMC-52D | |
| 0.00032 | - |
irreversible inhibition, IC50: 0.000320 mM | Homo sapiens | estatin B | |
| 0.00032 | - |
irreversible inhibition, IC50: 0.000320 mM | Homo sapiens | TMC-52A | |
| 0.00035 | - |
IC50: 0.00035 mM | Homo sapiens | Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6R)-4,4-dioxido-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide | |
| 0.00043 | - |
IC50: 0.00043 mM | Homo sapiens | Nalpha-[(benzyloxy)carbonyl]-N-[(3S,4R)-2-oxo-4-phenoxyazetidin-3-yl]-L-phenylalaninamide | |
| 0.00046 | - |
irreversible inhibition, IC50: 0.000460 mM | Homo sapiens | TMC-52C | |
| 0.00047 | - |
IC50: 0.00047 mM | Homo sapiens | Nalpha-[(benzyloxy)carbonyl]-N-[(2R,3S)-2-(carboxyoxy)-4-oxoazetidin-3-yl]-L-phenylalaninamide | |
| 0.0005 | - |
IC50: more than 0.00050 mM | Homo sapiens | Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6R)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide | |
| 0.00055 | - |
IC50: 0.00055 mM | Homo sapiens | 5,7-dihydroxy-2-(4-hydroxy-3-[7-methoxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one | |
| 0.00071 | - |
IC50: 0.00071 mM | Homo sapiens | benzyl [(1S)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)carbamoyl)-2-methylpropyl]carbamate | |
| 0.0011 | - |
IC50: 0.0011 mM | Homo sapiens | acetyl-Leu-Phe-arginal | |
| 0.00168 | - |
IC50: 0.00168 mM | Homo sapiens | 5,7-dihydroxy-2-(4-hydroxy-3-[7-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one | |
| 0.00175 | - |
IC50: 0.00175 mM | Homo sapiens | 5,7-dihydroxy-2-(4-hydroxy-3-[7-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]phenyl)-4H-chromen-4-one | |
| 0.00176 | - |
IC50: 0.00176 mM | Homo sapiens | Nalpha-[(benzyloxy)carbonyl]-N-[(5R,6S)-7-oxo-4-oxa-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide | |
| 0.00205 | - |
IC50: 0.00205 mM | Homo sapiens | mizaridine | |
| 0.0026 | - |
IC50: 0.0026 mM | Homo sapiens | N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline | |
| 0.00945 | - |
IC50: 0.00945 mM | Homo sapiens | benzyl [(1R)-2-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-2-methylpropyl)amino)-1-methyl-2-oxoethyl]carbamate | |
| 0.0164 | - |
IC50: 0.0164 mM | Homo sapiens | Nalpha-[(benzyloxy)carbonyl]-N-[(6R)-4-oxido-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-L-phenylalaninamide | |
| 0.021 | - |
IC50: 0.021 mM | Homo sapiens | Na-[(benzyloxy)carbonyl]-N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-phenylalaninamide | |
| 0.0229 | - |
IC50: 0.0229 mM | Homo sapiens | benzyl [(1R)-1-([2-hydroxy-1-methyl-2-(3-oxo-2-phenylcycloprop-1-en-1-yl)ethyl]carbamoyl)-2-methylpropyl]carbamate | |
| 0.029 | - |
IC50: 0.0290 mM | Homo sapiens | benzyl [(1R)-1-((1-[hydroxy(3-oxo-2-phenylcycloprop-1-en-1-yl)methyl]-4-methylpentyl)carbamoyl)-2-methylpropyl]carbamate | |
| 0.037 | - |
IC50: 0.037 mM | Homo sapiens | benzyl N-(3-methoxy-1,2,4-thiadiazolidin-5-yl)-L-alanyl-L-phenylalaninate | |
| 0.074 | - |
IC50: 0.074 mM | Homo sapiens | N-(3-phenyl-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline | |
| 0.1 | - |
IC50: more than 0.1 mM | Homo sapiens | benzyl [(1R)-1-([1-benzyl-2-hydroxy-2-(3-oxo-2-phenylcycloprop-1-en-1-yl)ethyl]carbamoyl)-2-methylpropyl]carbamate | |
| 0.3 | - |
IC50: 0.300 mM | Homo sapiens | N-(3-carboxy-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline | |
| 0.367 | - |
IC50: 0.367 mM | Homo sapiens | 3-methylbutyl N-[(3-methoxy-1,2,4-thiadiazolidin-5-yl)carbamoyl]-L-leucyl-L-prolinate | |
| 0.39 | - |
IC50: 0.390 mM | Homo sapiens | N-[(3-methoxy-1,2,4-thiadiazolidin-5-yl)carbamoyl]-L-leucyl-L-proline | |
| 0.447 | - |
IC50: 0.447 mM | Homo sapiens | N-(3-methyl-1,2,4-thiadiazolidin-5-yl)-L-leucyl-L-proline | |
| 4.4 | - |
IC50: 4.4 mM | Homo sapiens | ethyl 1-[(2R)-2-((1S)-1-(acetyloxy)-2-[((N-[(2,4-difluorophenyl)carbonyl]-L-phenylalanyl)amino)oxy]-2-oxoethyl)pentanoyl]prolinate | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
